Targeted drug tested for Hard-to-Treat cancers with specific genetic flaw
NCT ID NCT04617054
Summary
This study tested an oral drug called AB-106 (taletrectinib) for people with advanced solid tumors that had spread and contained a specific genetic change called an NTRK fusion. The goal was to see if the drug could shrink or control these difficult-to-treat cancers. The trial was open to adults whose cancer had worsened after standard treatments and was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.